Beyond Air
Beyond Air is revolutionizing nitric oxide therapy with its LungFit product family, which uses patented Ionizer™ technology to generate on-demand nitric oxide from room air. The company has a robust pipeline addressing respiratory therapeutic areas, cancer, and autism spectrum disorder, and operates from Garden City, NY, and Rehovot, Israel.
LungFit® PH FDA Approval
LungFit® PH has received Pre-Market Approval (PMA) from the FDA. This product is designed to treat term and near-term neonates with hypoxic respiratory failure, also known as persistent pulmonary hypertension of the newborn (PPHN).
Patented Ionizer™ Technology
Beyond Air's LungFit products leverage the patented Ionizer™ technology, which generates unlimited and on-demand nitric oxide using room air. This innovative approach eliminates the need for high-pressure nitric oxide cylinders, thus reducing inventory and storage requirements in hospitals.
Pipeline and Therapeutic Areas
Beyond Air has a robust pipeline of products targeting multiple therapeutic areas including respiratory diseases, cancer, and autism spectrum disorder. Products like LungFit® PRO and LungFit® GO are part of this pipeline, aimed at addressing community-acquired viral pneumonia (VCAP) and nontuberculous mycobacteria (NTM) lung infections, respectively.
Global Presence and Partnerships
Beyond Air has partnered with Getz Healthcare to commercialize its products in 10 Asian countries, excluding Japan. The company is headquartered in Garden City, NY, and has an additional office in Rehovot, Israel. It is committed to expanding its global footprint through strategic partnerships.
Research and Clinical Trials
Beyond Air is conducting various clinical trials for its investigational devices. For example, LungFit® PRO is undergoing a U.S. pilot trial for patients hospitalized with community-acquired viral pneumonia, and a trial for LungFit® GO is planned for U.S. patients with nontuberculous mycobacteria in 2025, pending FDA discussions.